Form 4: ADMA Biologics CEO Plans Option Exercise, Share Sale

ADMA Biologics' President and CEO, Adam S. Grossman, filed a Form 4 detailing a future exercise of stock options and sale of common stock under a 10b5-1 trading plan.

Summary

• Adam S. Grossman, President and CEO of ADMA Biologics, plans to exercise 15,000 stock options at an exercise price of $5.40 per share on December 15, 2025.
• Concurrently, Grossman intends to sell a total of 21,000 shares of common stock (15,000 shares and 6,000 shares) at an anticipated price of $19.79 per share on December 15, 2025.
• These transactions are scheduled to occur as part of a Rule 10b5-1 trading plan established on December 5, 2024.
• Following these planned transactions, Grossman will directly beneficially own 2,007,850 shares of common stock, which includes various tranches of unvested Restricted Stock Units (RSUs) and previously owned shares.
• Grossman also indirectly beneficially owns 1,143,426 shares through Areth, LLC, and 580,957 shares through Hariden, LLC, entities where he holds control or managing member positions.
• He will retain 720,950 unexercised stock options with an exercise price of $5.40, granted on February 26, 2024, which vest through February 26, 2028, and expire on February 26, 2034.

Sentiment

Score: 7

Explanation: The filing details a planned, routine insider transaction by the CEO to monetize equity compensation. The significant profit from the option exercise is positive, and the executive's continued substantial holdings indicate ongoing confidence in the company. The pre-scheduled nature of the transaction under a 10b5-1 plan reduces any negative sentiment associated with insider selling.

Positives

• The planned sale price of $19.79 per share is significantly higher than the option exercise price of $5.40, indicating a substantial unrealized gain on the options.
• The transactions are being conducted under a pre-arranged Rule 10b5-1 trading plan, which demonstrates a systematic approach to managing equity compensation and mitigates concerns about opportunistic insider trading.
• Grossman will retain a substantial direct and indirect beneficial ownership in the company, signaling continued alignment with shareholder interests despite the partial sale.

Negatives

• The planned sale of 21,000 shares by a key executive, even under a 10b5-1 plan, represents a reduction in direct equity exposure to the company's stock.

Future Outlook

This filing does not contain forward-looking statements or guidance beyond the scheduled execution of the described transactions.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a common practice in the biotechnology and pharmaceutical industries for executives to manage their equity compensation and diversify their personal holdings in a compliant manner.

Related Party Transactions

• Adam S. Grossman is a control person of Areth, LLC, which beneficially owns 1,143,426 shares of common stock.
• Adam S. Grossman is the managing member of Hariden, LLC, which beneficially owns 580,957 shares of common stock.

Stakeholder Impact

• Shareholders may view the executive's planned profitable option exercise and sale as a positive indicator of value creation, especially given the significant difference between the exercise and sale prices.
• The pre-arranged nature of the transaction (10b5-1 plan) helps assure stakeholders that the executive's actions are not based on undisclosed material information.

Next Steps

• Execution of the planned stock option exercise and share sales on December 15, 2025.
• Continued vesting of the remaining 720,950 stock options through February 26, 2028.
• Continued vesting of various tranches of unvested RSUs granted between March 2022 and February 2025.

Key Dates

Recommendation

This Form 4 filing details a pre-scheduled insider transaction by the CEO, involving the exercise of stock options and a subsequent sale of shares under a Rule 10b5-1 plan. This is a routine event for executives managing their equity compensation and is not indicative of a change in the company's fundamental outlook or the CEO's long-term commitment, as substantial direct and indirect holdings are retained. Therefore, this filing alone does not warrant a change in investment recommendation, and a 'hold' position is appropriate, with investors continuing to evaluate the company based on its broader financial performance and strategic developments.

Keywords

ADMA Biologics, ADMA, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Adam S. Grossman, CEO, Director, 10b5-1 Plan, Equity Compensation